Core Insights - Corcept Therapeutics Incorporated (NASDAQ:CORT) is focused on developing medications that modulate cortisol effects to treat severe disorders, including oncologic conditions [1] - H.C. Wainwright upgraded CORT's stock to "Buy" and raised its price target from $90 to $105, with the stock priced at approximately $41.87 at the time of the announcement [1][5] Stock Performance - Following the upgrade, CORT's stock has seen a notable increase, currently priced at $41.30, reflecting a 13.74% increase with a change of $4.99 [3][5] - The stock has fluctuated between a low of $40.46 and a high of $52.84 during today's trading [3] - Over the past year, the stock reached a high of $117.33 and a low of $32.99 [3] Clinical Trial Results - The upgrade coincides with significant developments, particularly the successful results from the ROSELLA Phase 3 trial, which tested the combination of relacorilant and nab-paclitaxel for treating platinum-resistant ovarian cancer [2] - The trial demonstrated a 35% reduction in the risk of death for patients receiving the combination therapy [2][5] - The combination therapy was well-tolerated, with adverse events similar to those experienced with nab-paclitaxel monotherapy [4] Market Capitalization and Trading Volume - Corcept's market capitalization is approximately $4.34 billion, with a trading volume of 5,304,058 shares [4]

Core Insights - Corcept Therapeutics is focused on developing drugs for severe metabolic and oncologic disorders, particularly in cortisol modulation therapies [1] - The company faces competition from Teva Pharmaceuticals and Mylan in similar therapeutic areas [1] Stock Performance - Analyst Swayampakula Ramakanth from H.C. Wainwright set a new price target of $105 for CORT, indicating a potential increase of approximately 46.8% from the current price of $41.47 [2][6] - Corcept's stock has seen a significant increase, with trading volume reaching over 3 million shares following successful results from the ROSELLA Phase 3 trial [3][6] - The current stock price is $41.61, reflecting a 14.60% increase with a change of $5.30, and the stock has fluctuated between a low of $40.46 and a high of $43.50 during the day [5] Clinical Trial Results - The ROSELLA Phase 3 trial tested relacorilant and nab-paclitaxel in treating platinum-resistant ovarian cancer, showing a 35% reduction in the risk of death for patients receiving the combination therapy [3][6] - The median overall survival for patients treated with relacorilant was 16 months, compared to 11.9 months for those on nab-paclitaxel alone, marking an improvement of 4.1 months [4][6] - The combination therapy was well-tolerated, with adverse events similar to those experienced with nab-paclitaxel monotherapy [4] Market Capitalization - Corcept's market capitalization stands at approximately $4.38 billion, with today's trading volume at 4,189,821 shares on the NASDAQ exchange [5]

Relacorilant联合白蛋白紫杉醇治疗的耐受性良好，与其已知的安全性特征一致。值得注意的是，联合治 疗组不良事件的类型、发生频率及严重程度与白蛋白紫杉醇单药治疗组相当。Relacorilant在带来疗效获 益的同时，并未增加患者的安全性负担。 Corcept此前曾宣布，ROSELLA试验同样达到了无进展生存期(PFS)改善这一主要终点，该结果由盲法独 立中心评估(BICR)确认。与单用白蛋白紫杉醇相比，接受relacorilant联合治疗患者的疾病进展风险降低 了30%(HR=0.70，p=0.008)。 Relacorilant是一种口服选择性糖皮质激素受体(GR)拮抗剂，可通过与GR结合而不与机体其他激素受体 结合，从而调节皮质醇活性。Corcept正在推进relacorilant在卵巢癌及多种其他严重疾病中的开发，包括 内源性高皮质醇症以及子宫内膜癌、宫颈癌、胰腺癌和前列腺癌。该药物已被美国FDA和欧盟委员会 (EC)授予用于治疗高皮质醇症的孤儿药资格，并被EC授予用于治疗卵巢癌的孤儿药资格。 分析显示，与仅用白蛋白紫杉醇相比，接受relacorilant联合白蛋白紫杉醇患者的死亡风险降低了35% ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) stock is trading higher on Thursday, with a session volume of 3.06 million.The company’s ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer met its overall survival (OS) primary endpoint.DataIn ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 35% reduction in the risk of death compared to patients treated with nab-paclitaxel alone (hazard ratio: ...

Corcept Therapeutics said on Thursday that its experimental cancer drug met the main goal in a late-stage study. ...

Core Viewpoint - Corcept Therapeutics experienced a significant decline in share price, dropping 50% after receiving a complete response letter from the FDA regarding its treatment relacorilant for hypercortisolism, leading to a loss of over $3.6 billion in market capitalization [1][3]. Company Overview - Corcept Therapeutics has previously promoted relacorilant's efficacy and commercial potential, claiming that clinical trial patients showed meaningful improvements in hypercortisolism symptoms [3]. - The company expressed confidence in achieving annual revenues of $3 billion to $5 billion from its hypercortisolism business within three to five years [3]. FDA Response - The FDA's complete response letter indicated that additional evidence of effectiveness was required for relacorilant, contradicting Corcept's previous assurances about the drug's progress toward approval [3]. - A report noted that the likelihood of loss of blood pressure control was 83% lower in the relacorilant group compared to placebo, which may have influenced the FDA's decision [3]. Legal Investigation - Hagens Berman, a national shareholder rights law firm, has initiated an investigation into whether Corcept misled investors regarding relacorilant's efficacy and commercial prospects [2][4]. - The firm is encouraging investors who suffered losses to come forward and discuss their rights [2][4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Corcept Therapeutics and its officers or directors following a significant stock price drop after the FDA's Complete Response Letter regarding relacorilant [1][3]. Group 1: Company Overview - Corcept Therapeutics Incorporated is a biopharmaceutical company focused on developing treatments for patients with conditions related to cortisol [3]. - The company’s stock price experienced a dramatic decline of $35.40 per share, or 50.42%, closing at $34.80 per share on December 31, 2025, after the FDA issued a Complete Response Letter for its New Drug Application for relacorilant [3]. Group 2: Regulatory Developments - On December 31, 2025, the FDA issued a Complete Response Letter regarding Corcept's New Drug Application for relacorilant, indicating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness was required for a favorable benefit-risk assessment [3].

Core Insights - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following a Complete Response Letter (CRL) from the FDA regarding its new drug application for relacorilant [1][2] - The FDA's decision was based on the need for additional evidence of effectiveness despite acknowledging previous trial results [2] - Following the announcement, Corcept's stock price experienced a significant drop of $31.42, or 44.76%, reaching a new 52-week low of $38.78 per share [2][3] Company Developments - The FDA's CRL was issued on December 31, 2025, denying approval for relacorilant as a treatment for hypertension secondary to hypercortisolism [1] - The stock price decline marks a significant downturn, with levels not seen since September 2024 [3] Legal Context - Levi & Korsinsky LLP has initiated an investigation into Corcept, indicating potential legal ramifications for the company and its investors [1][4] - The firm has a strong track record in securities litigation, having secured substantial recoveries for shareholders in the past [4]

Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the most promising growth stocks according to analysts. According to an Investing.com report, William Guyer, Chief Development Officer at Corcept Therapeutics Incorporated (NASDAQ:CORT), sold 20,000 shares of common stock valued at $703,656 on January 6. Earlier on January 2, Swayampakula Ramakanth, an analyst at H.C. Wainwright, trimmed the price target on Corcept Therapeutics Incorporated (NASDAQ:CORT) to $90 from $145, while maintaining a ‘Buy’ ...

Core Insights - Corcept Therapeutics and Amicus Therapeutics reported Q3 2025 results, showcasing contrasting profitability levels within the rare disease biotech sector [1] Company Summaries Corcept Therapeutics - Corcept Therapeutics is positioned as a profitable entity within the rare disease biotech space, indicating strong financial performance [1] Amicus Therapeutics - Amicus Therapeutics, in contrast, is highlighted as being at the opposite end of the profitability spectrum, suggesting challenges in achieving financial stability [1]